clinical trial · NCT07102381
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
HER2-positive Breast CancerBreast CancerZanidatamabPaclitaxelDocetaxelCarboplatinTrastuzumabPertuzumab
brief summary
The purpose of this study is to see if zanidatamab is safe and effective, when combined with chemotherapy, in treating people who has Human Epidermal Growth Factor Receptor 2 (HER2)-positive, early-stage breast cancer
started
Sep 24, 2025
primary completion
Jan 1, 2028
completion
Aug 1, 2030
last updated
Jul 2, 2026
official title
A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol